Антифосфолипидный синдром - часть 24

101

human 

β

2

glycoprotein I to phospholipids based

on its crystal structure. EMBO J 1999; 18: 5166—
5174.

17. Schwarzenbacher R, Zeth K, Diederichs K,

Gries A, Kostner GM, Laggner P, Prassl R.
Crystal structure of human 

β

2

glycoprotein I:

implications for phospholipid binding and the
antiphospholipid syndrome. EMBO J 1999; 18:
6228—6239.

18. Lutters BCH, de Droot P, Derksen RHWM.

β

2

glycoprotein 1 — a key player in the antiphos

pholipid syndrome. JMAJ 2002; 4 (Suppl): 958—
962.

19. Hunt J, Krilis S. The fifth domain of beta2

glycoprotein I containes a phosphilipid binding
site (cys

281

cys

288

), and region recognised by anti

cardiolipin antibodies. J Immunol 1994; 152:
653—659.

20. Kertesz Z, Yu B, Steinkasserer A, et al.

Characterization of binding of human beta2gly
coprotein I to cardiolipin. Biochem J 1995;
310:315—321.

21. Wurm H. Beta2glycoprotein I (apol

ipoprotein H) interactions with phospholipid vesi
cles. Int J Biochem 1984; 16: 511—515.

22. Kochl S, Fresser F, Lobentanz E, et al.

Novel interaction of apolipoprotein (a) with 

β

2



glycoprotein I mediated by the kringle IV domain.
Blood 1997; 90: 1482—1489.

23. Rojkjaer R, Klaerke DA, Schousboe I.

Characterisation of the interaction between 

β

2



glycoprotein I and calmodulin, and identification
of the binding sequence in 

β

2

glycoprotein I.

Biochem Biophys, Acta Protein Struct Mol
Enzymol 1997; 1339: 217—225.

24. Ma K, Zhang JC. Wan K, et al. The bind

ing of 

β

2

glycoprotein I (

β

2

GPI) to endothelial

cells mediated through a high affinity interaction
with annexin II. Blood 1998; 92L; 172A.

25. Chonn A, Semple SC, Cullis PR. 

β

2

glyco

protein I is a major protein associated with very
rapidly cleared liposomes in vitro, suggesting a sig
nificant role in the immune clerance of "nonself"
particles J Biol Chem 1995; 270: 2584525849.

26. Balasubramanian K, Chandra J, Schroit

AJ. Immune clearance of phosphatidylserine
expressing cells by phagocytes. The role of 

β

2

gly

coprotein I is macrophage recognition. J Biol
Chem 1997; 272: 31113—31117.

27. Borchman D, Harris EN, Pierangelli SS,

Lamba OP. Interactions and molecular structure
of cardiolipin and beta2glycoprotein 1 (beta2
GP1). Clin Exp. Immunol 1995; 102:37.

28. Chonn A, Semple SC, Cullis PR. 

β

2



Glycoprotein I is a major protein associated with
very rapidly cleared liposomes in vivo, suggesting
a significant role in the immune clearance of
"nonself" particles. J Biol Chem 1995; 270:
25845—25849.

29. Manfredi AA, Rovere P, Galati G, Heltai S,

Bozzolo E, Soldini L, Davoust J, Balestrieri G,
Tincani A, Sabbadini MG. Apoptotic cell clear
ance in systemic lupus erythematosus, I: opsoniza
tion by antiphospholipid antibodies. Arthritis
Rheum 1998; 41: 205—214.

30. Merten M, Motamedy S, Ramamuthy S, et

al. Sulfatides. Targets for antiphospholipid anti
bodies. Circulation 2003; 108: 2082—2087.

31. Cleve H. Genetic studies on the deficiency of

b2glycoprotein I of human serum. Humangenetik
1968; 5: 294—304.

32. Yasuda S, Tsutsumi A, Chiba H, Yanai H,

Miyoshi Y, Takeuchi R, Horita T, Atsumi T,
Ichikawa K, Matsuura E, Koike T. 

β

2

Glycopro

tein I deficiency: prevalence, genetic background
and effects on plasma lipoprotein metabolism and
hemostasis. Atherosclerosis 2000; 152: 337—346.

33. Bancsi LF, van der Linden IK, Bertina RM.

β

2

Glycoprotein I deficiency and the risk of

thrombosis. Thromb Haemost 1992; 67: 649—
653.

34. Sheng Y, Reddel SW, Herzog H, Wang YX,

Brighton T, France MP, Robertson SA, Krilis SA.
Impaired thrombin generation in 

β

2

glycoprotein

I null mice. J Biol Chem 2001; 276: 13817—
13821.

35. Gharavi AE, Sammaritano LR, Wen J,

Elkon KB. Induction of antiphospholipid antibod
ies by immunization with 

β

2

glycoprotein I

(apolipoprotein H). J Clin Invest 1992; 90:
1105—1109.

36. Gharavi AE, Sammaritano LR, Bovastro

JL, Wilson WA. Specificities and characteristics
of 

β

2

glycoprotein I induced antiphpspholipid

antibodies. J Lab Clin Med 1995; 125: 775—
778.

37. Reddel SW, Wang YX, Sheng YH, Krilis SA.

Epitope studies with anti

β

2

glycoprotein I anti

ГЛАВА 5. Патогенетические механизмы антифосфолипидного синдрома

Насонов Е.Л. Антифосфолипидный синдром

102

bodies from autoantibody and immunized
sources. J Autoimmun 2000; 15: 91—96.

38. McNeeley PA, Dlott JS, Furie RA, Jack

RM, Ortel TL, Triplett DA, Victoria EJ, Linnik
MD. 

β

2

Glycoprotein Idependent anticardi

olipin antibodies preferentially bind the amino
terminal domain of 

β

2

glycoprotein I. Thromb

Haemost 2001; 86: 590—595.

39. Палькеева МЕ, Сидорова МВ, Кузнецо

ва ТВ, Кобылянский АГ, Тищенко ВА, Насо
нов ЕЛ, Беспалова ЖД, Евстигнеева РП.
Синтез и исследование антигенных свойств
пептидных фрагментов бета2гликопротеи
наI. Биоорганическая химия, 1996; 9: 678—
685. 

40. Roubey RAS, Eisenberg RA, Harper MF,

Winfield JB. "Anticardiolipin" antibodies recog
nize 

β

2

glycoprotein I in the absence of phospho

lipid. Importance of antigen density and bivalent
binding. J Immunol 1995; 154: 954—960.

41. Tincani A, Spatola L, Pratt E, et al. The

anti

β

2

glycoprotein I activity in human anti

phospholipid syndrome sera is due to monoreac
tive lowaffinity autoantibodies directed to epitope
located on native 

β

2

glycoprotein I and preserved

during species evolution. J Immunol 1996; 157:
5732—5738.

42. Amengual O, Atsumi T, Koike T. Specifici

ties, properties, and clinical significance of anti
prothrombin antibodies. Arthritis Rheum 2003;
48: 886—895.

43. de Groot PG, Derksen RHWM. The influ

ence of antiphospholipid antibodies on the protein
C pathway. In Hughes Syndrome, Antiphospho
lipid Syndrome. Edited by Khamashta MA.
London: Springer—Verlag; 2000; 307—316.

44. Dahlback B. Physiological anticoagulation:

resistance to activated protein C and venous
thromboembolism. J Clin Invest 1994; 94: 923—
927.

45. Koike T, Hughes GRV. Binding of anticar

diolipin antibodies to protein C via beta 2 glyco
protein I: a possible mechanism in inhibitory
effect of antiphospholipid antibodies on the pro
tein C system. Clin Exp Immunol 1998, 112:
325—333.

46. Galli M, Ruggeri L, Barbui T. Differential

effects of antibeta 2 glycoprotein I and antipro
thrombin antibody on the anticoagulant activity of

activated protein C. Blood 1998, 91: 1999—
2004. 

47. Male C, Mitchell L, Julian J, et al.

Acquired activated protein C resistance is asso
ciated with lupus anticoagulants and thrombotic
events in pediatric patients with systemic lupus
erythematosus. Blood 2001; 97: 844— 849. 

48. Ieko M, Sawada KI, Koike T, et al. The

putative mechanism of thrombosis in antiphos
pholipid syndrome: impairment of the protein C
and the fibrinolytic systems by monoclonal anti
cardiolipin antibodies. Semin Thromb Hemost
1999; 25: 503— 507.

49. Esmon CT. The anticoagulant and anti

inflammatory roles of the protein C anticoagulant
pathway. J Autoimmun 2000; 15: 113—116.

50. Ames PR, Tommasino C, Iannaccone L,

Brillante M, Cimino R, Brancaccio V. Coagu
lation activation and fibrinolytic imbalance in
subjects with idiopathic antiphospholipid antibod
iesa crucial role for acquired free protein S defi
ciency. Thromb Haemost 1996; 76: 190—194.

51. Crowther MA, Johnston M, Weitz J,

Ginsberg JS. Free protein S deficiency may be
found in patients with antiphospholipid antibodies
who do not have systemic lupus erythematosus.
Thromb Haemost 1996; 76: 689—691.

52. Shibata S, Harpel PC, Gharavi A, Rand J,

Fillit H. Autoantibodies to heparin from patients
with antiphospholipid antibody syndrome inhibit
formation of antithrombin IIIthrombin complex
es. Blood 1994; 83: 2532—2540.

53. Schousboe I, Rasmussen MS. Synchro

nized inhibition of the phospholipid mediated
autoactivation of factor XII in plasma by
beta2glycoprotein I and antibeta2glycopro
tein I. Thromb Haemost 1995; 73: 798—804.

54. Jones DW, Gallimor MJ, MacKie IJ, et al.

Reduced factor XII levels in patients with the
antiphospholipid syndrome are associated with
antibodies to factor XII. Br J Haematol 2000;
110: 721— 726. 

55. Sugi T, Makino T: Plasma contact system,

kallikrein/kinin system and antiphospholipid
protein antibodies in thrombosis and pregnancy. J
Reprod Immunol 2000; 47: 169— 184.

56. Dueymes M, Levy Y, Ziporen L, Jamin C,

Piette JC, Shoenfeld Y, Youinou P. Do some
antiphospholipid antibodies target endothelial

103

cells? Ann Med Interne (Paris). 1996; 147
(Suppl 1): 22—23.

57. Matsuda J, Gotoh M, Gohchi K, Kawasugi

K, Tsukamoto M, Saitoh N. Antiendothelial cell
antibodies to the endothelial hybridoma cell line
(EAhy926) in systemic lupus erythematosus
patients with antiphospholipid antibodies. Br J
Haematol 1997; 97: 227—232.

58. Navarro M, Cervera R, Teixido M, Reverter

JC, Font J, Lopez Soto A, Monteagudo J, Escolar
G, Ingelmo M. Antibodies to endothelial cells and
to 

β

2

glycoprotein I in the antiphospholipid syn

drome: prevalence and isotype distribution. Br J
Rheumatol 1996; 35: 523—528.

59. Le Tonqueze M, Salozhin K, Dueyems M,

Nasonov E, Piette JC, Youinou P. Role of 

β

2

gly

coprote in the antiphospholipid antibody binding to
endothelial cells. Lupus, 1995; 7: 179—186.

60. Meroni PL, Raschi E, Camera M, Testoni

C, Nicoletti F, Tincani A, Khamashta MA,
Balestrieri G, Tremoli E, Hess DC. Endothelial
activation by aPL: a potential pathogenetic mech
anism for the clinical manifestations of the syn
drome. J Autoimmun. 2000; 15: 237—240.

61. Keying M, Simantov R, JingChuan Z, et

al. High affinity binding of 

β

2

glycoprotein I to

human endothelial cells is mediated by Annexin
II. J Biol Chem 2000; 20: 15541— 15548.

62. Afek A, Shoenfeld Y, Manor R, et al.

Increased endothelial cell expression of
alpha3beta1 integrin in cardiac valvulopathy in
primary (Hughes) and secondary antiphospho
lipid syndrome. Lupus 1999; 8: 502— 507. 

63. Pierangeli SS, ColdenStanfield M, Liu X,

et al. Antiphospholipid antibodies from antiphos
pholipid syndrome patients activate endothelial
cells in vitro and in vivo. Circulation 1999; 99:
1997— 2002. 

64. Pierangeli SS, Espinola RG, Liu X, et al.

Thrombogenic effects of antiphospholipid anti
bodies are mediated by intercellular cell adhesion
molecule1, vascular cell adhesion molecule1,
and Pselectin. Circ Res 2001; 88: 245— 250.

65. Del Papa N, Sheng YH, Raschi E, et al.

Human 2glycoprotein I binds to endothelial
cells through a cluster of lysine residues that are
critical for anionic phospholipid binding and
offers epitopes for anti2glycoprotein I antibod
ies. J Immunol 1998; 160: 5572— 5578.

66. Meroni PL, Raschi E, Testoni C, et al.

Statins prevent endothelial cell activation induced
by antiphospholipid (anti

β

2

glycoprotein I)

antibodies: effect on the proadhesive and proin
flammatory phenotype. Arthritis Rheum 2001; 44:
2870—2878.

67. Raschi E, Testoni C, Bosisio D, et al. Role

of the MyD88 transduction signaling pathway in
endothelial activation by antiphospholipid anti
bodies. Blood 2003; 101: 3495—3500.

68. Александрова ЕН, Новиков АА., Решет

няк ТМ, Клюквина НГ, Решетняк ДВ, Самсо
нов МЮ, Насонов ЕЛ. Растворимые молеку
лы адгезии при антифосфолипидном синдро
ме, связанном с системной красной волчан
кой, и первичном антифосфолипидном синд
роме. Терапевт. архив, 2002; 5; 23—27.

69. Kaplanski G, Cacoub P, Farnarier C, et al.

Increased soluble vascular cell adhesion molecule
1 concentrations in patients with primary or sys
temic lupus erythematosusrelated antiphospho
lipid syndrome: correlations with the severity of
thrombosis. Arthritis Rheum 2000; 43: 55— 64. 

70. Penn MS, Topol EJ. Tissue factor, the

emerging link between inflammation, thrombo
sis, and vascular remodeling. Circ Res 2001;
89:1—2.

71. DobadoBerrios FM, LopezPedrera C,

Velasco F, Cuadrado MJ. The role of tissue fac
tor in the antiphospholipid syndrome. Arthritis
Rheum 2001; 44: 2467—2476.

72. Amengual O, Atsumi T, Khamashta MA.

Tissue factor in the antiphospholipid syndrome:
shifting the focus from coagulation to endotheli
um. Rheumatology 2003; 43: 1—3.

73. Branch DW, Rodgers GM. Induction of

endothelial cell tissue factor activity by sera from
patients with antiphospholipid syndrome: a possi
ble mechanism of thrombosis. Am J Obstet
Gynecol 1993; 168: 206—210.

74. Kornberg A, Renaudineau Y, Blank M,

Youinou P, Shoenfeld Y. Anti

β

2

glycoprotein I

antibodies and antiendothelial cell antibodies
induce tissue factor in endothelial cells. Isr Med
Assoc J 2000; 2 (Suppl 1): 27—31.

75. Cuadrado MJ, Buendia P, LopezPedrera

C, et al. Increased tissue factor expression in
monocytes from patients with antiphospholipid
syndrome depens on NFkB activation.

ГЛАВА 5. Патогенетические механизмы антифосфолипидного синдрома

Насонов Е.Л. Антифосфолипидный синдром

104

ACR/ARHP Annual Acientific Meeting 2003;
October 24—28, 322 (abst).

76. Martini F, Farsi A, Gori AM, Boddi M, Fedi

S, Domeneghetti MP, Passaleva A, Prisco D,
Abbate R. Antiphospholipid antibodies (aPL)
increase the potential monocyte procoagulant
activity in patients with systemic lupus erythe
matosus. Lupus 1996; 5: 206—211.

77. Visvanathan S, Geczy CL, Harmer JA,

McNeil HP. Monocyte tissue factor induction by
activation of 

β

2

glycoproteinIspecific T lym

phocytes is associated with thrombosis and fetal
loss in patients with antiphospholipid antibodies. J
Immunol. 2000; 165: 2258—2262.

78. Reverter JC, Tassies D, Font J, Monteagudo

J, Escolar G, Ingelmo M, Ordinas A. Hypercoa
gulable state in patients with antiphospholipid
syndrome is related to high induced tissue factor
expression on monocytes and to low free protein s.
Arterioscler Thromb Vasc Biol 1996; 16: 1319—
1326.

79. DunoyerGeindre S, De Moerloose P, Galve

De Rochemonteix B, et al. NFkB is an essential
intermediate in the activation of endothelial cells by
antibeta2glycoprotein I antibodies. Thromb
Haemost 2002; 88: 851—857.

80. Salemink I, Blezer R, Willems GM, Galli

M, Bevers E, Lindhout T. Antibodies to 

β

2

glyco

protein I associated with antiphospholipid syn
drome suppress the inhibitory activity of tissue
factor pathway inhibitor. Thromb Haemost 2000;
84: 653—656.

81. Adams MJ, Donohoe S, Mackie IJ,

Machin SJ. Antitissue factor pathway inhibitor
activity in patients with primary antiphospho
lipid syndrome. Br J Haematol 2001; 114: 375—
379.

82. Andree HAM, Hermens WT, Hemker HC,

Willems GM. Displacement of factor Va by
annexin V. In: Andree HAM, ed. Phospholipid
Binding and Anticoagulant Action of Annexin V.
Maastricht, The Netherlands: Universitaire Pers
Maastricht 1992: 73—85. 

83. Rand JH, Wu XX, Guller S, Gil J, Guha A,

Scher J, Lockwood CJ. Reduction of annexinV
(placental anticoagulant proteinI) on placental
villi of women with antiphospholipid antibodies
and recurrent spontaneous abortion. Am J Obstet
Gynecol 1994; 171: 1566—1572.

84. Rand JH, Wu XX, Guller S, Scher J, Andree

HAM, Lockwood CJ. Antiphospholipid immuno
globulin G antibodies reduce annexinV levels on
syncytiotrophoblast apical membranes and in cul
ture media of placental villi. Am J Obstet Gynecol
1997; 177: 918—923.

85. Vogt E, Ng AK, Rote NS. Antiphos

phatidylserine antibody removes annexinV and
facilitates the binding of prothrombin at the sur
face of a choriocarcinoma model of trophoblast
differentiation. Am J Obstet Gynecol 1997; 177:
964—972.

86. Rand JH, Wu XX, Andree HAM, Alexander

Ross JB, Rosinova E, GasconLema MG,
Calandri C, Harpel PC. Antiphospholipid anti
bodies accelerate plasma coagulation by inhibit
ing annexinV binding to phospholipids: a "lupus
procoagulant" phenomenon. Blood. 1998; 92:
1652—1660.

87. Carreras L, Forastiero R, Martinuzzo M:

Interaction between antiphospholipid antibodies
and eicosanoids. In Hughes Syndrome, Antiphos
pholipid Syndrome. Edited by Khamashta MA.
London: Springer—Verlag; 2000: 337—347. 

88. Lellouche F, Martinuzzo M, Said P, Maclouf

J, Carreras LO. Imbalance of thromboxane/
prostacyclin biosynthesis in patients with lupus anti
coagulant. Blood 1991; 78: 2894—2899.

89. Алекберова ЗС, Решетняк ТМ, Насонов

ЕЛ и др. Уровни тромбоксана и простацикли
на у больных системной красной волчанкой с
антифосфолипидным синдромом. Клин. меди
цина, 1994; 6: 31—35. 

90. Atsumi T, Khamashta MA, Haworth RS,

Brooks G, Amengual O, Ichikawa K, Koike T,
Hughes GR. Arterial disease and thrombosis in
the antiphospholipid syndrome: a pathogenic role
for endothelin 1. Arthritis Rheum 1998; 41: 800—
807.

91. Cho CS, Cho ML, Chen PP, et al.

Antiphospholipid antibodies induce monocyte
chemoattractant protein1 in endothelial cells. J
Immunol 2002; 168: 4209—4215.

92. Clancy RM, Amin AR, Abramson SB. The

role of nitric oxide in inflammation and immuni
ty. Arthritis Rheum 1998; 41: 1141—1151.

93. Кобылянский АГ, Кузнецова ТВ, Соболе

ва ГН и др. Определение оксида азота в сыво
ротке и плазме крови человека. Метод высо